The US-based eye-care company is also developing intraocular lens products, while low adoption of premium cataract procedures ...

The average one-year price target for Alcon Inc. - Depositary Receipt (BOVESPA:A2LC34) has been revised to R$43.42 / share. This is a decrease of 14.08% from the prior estimate of R$50.53 dated August ...

Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness. Alcon has received FDA approval for apraclonidine ophthalmic solution 0.125% (Brytly) redness relief ...

Alcon posted USD 2.82 billion revenue and USD 0.84 adjusted EPS in Q2. Alcon stock costs EUR 57.01 on October 9, 2026 after EUR 56.35. Alcon presented dry-eye, contact-lens and eye-care research at ...

Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand. Click for more details on ALC.

Alcon says newly approved BRYTLY reduces eye redness for up to 12 hours, with U.S. retail availability expected in the coming months.

Alcon (ISIN CH0432492467) was trading at EUR 59.03 at Lang & Schwarz on October 19, 2026 at 9:38 a.m. CEST. The company had ...

October 16, 2026, delivered 3 ophthalmic FDA approvals that, taken together, touch nearly every corner of the eye care ...

This is the first OTC eye drop with apraclonidine, although another drug in the class of alpha-2 adrenergic ...

The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness ...

FORT WORTH, Texas, September 29, 2026 - Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it will present new scientific research and ...

Alcon Inc. (NYSE: ALC), a Swiss-based leader in the healthcare sector, is drawing significant attention from investors ...